ライフサイエンスコーパス: adverse reaction

1 All patients tolerated the drug without any adverse reaction.

2 reviously known to be a linezolid-associated adverse reaction.

3 ation of safety information for this serious adverse reaction.

4 s may be at risk for this potentially severe adverse reaction.

5 ulocytosis is a potentially life-threatening adverse reaction.

6 ure to detect potential rare vaccine-related adverse reactions.

7 ing of processed foods is mandatory to avoid adverse reactions.

8 h prediction and prevention of these serious adverse reactions.

9 ustained unresponsiveness and a reduction in adverse reactions.

10 and followed up for 3 months had no serious adverse reactions.

11 er antibiotics in patients with a history of adverse reactions.

12 cause of an increased risk of statin-induced adverse reactions.

13 isk factors" for failure, visual acuity, and adverse reactions.

14 sociations between drugs and their potential adverse reactions.

15 ocol restricting collection and reporting to adverse reactions.

16 Medicine to restore its surveys of reported adverse reactions.

17 the pharmacovigilance plan was restricted to adverse reactions.

18 peanut allergy may be limited by the risk of adverse reactions.

19 y specimens from 28 control subjects with no adverse reactions.

20 acotherapy, as well as to reduce caregivers' adverse reactions.

21 use of these drugs is associated with severe adverse reactions.

22 he intended therapeutic effects and frequent adverse reactions.

23 to determine the behavioral significance of adverse reactions.

24 use of such drugs is associated with severe adverse reactions.

25 The vaccine was immunogenic and caused no adverse reactions.

26 the rate or severity of clinically relevant adverse reactions.

27 g antirheumatic drugs increase both types of adverse reactions.

28 matory lesions without serious infections or adverse reactions.

29 ll tolerated with rare (<2% per person-year) adverse reactions.

30 g early in the process allows monitoring for adverse reactions.

31 erapeutic agents to treat vaccine-associated adverse reactions.

32 PNA therapy because of the high incidence of adverse reactions.

33 sensitivity, thrombocytopenia, and more rare adverse reactions.

34 of the direct-rechallenge group were due to adverse reactions.

35 erienced mild-to-moderate treatment-limiting adverse reactions.

36 , and the potential for irritation and other adverse reactions.

37 sily achievable by NUC therapy, with limited adverse reactions.

38 ons derived from their secondary effects and adverse reactions.

39 ode: drugs, protein targets, indications and adverse reactions.

40 nstitutes an important cause of food-related adverse reactions.

41 thways to predict new indications as well as adverse reactions.

42 efits, but have been associated with serious adverse reactions.

43 edure, and in a few cases potential systemic adverse reactions.

44 argeted to improve therapy while attenuating adverse reactions.

45 ssociation between, radiopharmaceuticals and adverse reactions.

46 ety, assessed by the number and intensity of adverse reactions.

47 no changes in nutritional parameters and no adverse reactions.

48 eports) were the 3 most frequently occurring adverse reactions.

49 men, recommended boosters, and potential for adverse reactions.

50 All systemic adverse reactions (0.8% of all injections in the verum g

51 in 149 patients (79.7% of patients with any adverse reaction, 0.530% of overall population).

52 r 2 potentially alemtuzumab infusion-related adverse reactions (102 [62%] vs 22 [13%]).

53 There were no differences in serious adverse reactions (16 reactions in 14 participants recei

54 Fewer controls had adverse reactions (29 of 111 [26%]) than did participant

55 Six patients had no adverse reactions, 3 had minor bleeding, 6 required bloo

56 of 265 women reported at least one solicited adverse reaction: 39 (45%) of 87 women with HIV and low

57 d cephalosporin-associated serious cutaneous adverse reactions (95% CI, 0-1 in 217,291).

58 d for those patients without hypertension or adverse reactions above grade 2.

59 Sheffield NARCOS (National Adverse Reactions Advisory Service) investigates suspect

60 95% confidence interval for experiencing an adverse reaction after ephedra use compared with other h

61 In conclusion, many patients experience mild adverse reactions after completing oral immunotherapy an

62 l as between disease recurrence and scars or adverse reactions after surgery or radiation therapy.

63 literature pertaining to recently discovered adverse reactions; all studies found PPIs are being over

64 uicide gene grants a mechanism of control of adverse reactions, allowing safe infusion after partiall

65 One adverse reaction (an exacerbation of pain after the init

66 was also associated with significantly more adverse reactions and early study withdrawal.

67 formula B-FAHF-2 (BF2) ameliorates PN/TN OIT adverse reactions and enhances persistence of a tolerant

68 Blood from all three patients with severe adverse reactions and from one of six with moderate reac

69 ventional therapy for TTP, may cause serious adverse reactions and is ineffective in some patients.

70 itivity is a major cause of severe cutaneous adverse reactions and is strongly associated with the HL

71 e trial was stopped early because of serious adverse reactions and limited evidence for seizure reduc

72 Adverse reactions and mechanistic changes were assessed.

73 pharmacogenomics can reduce the incidence of adverse reactions and on the resulting clinical, societa

74 well as provide an outline of the potential adverse reactions and side-effects that might affect ane

75 mise, treatment is frequently complicated by adverse reactions and, even when successful, has limited

76 rms (eg, serious infections, immune-mediated adverse reactions) and benefits (eg, rapid Hb improvemen

77 rms (eg, serious infections, immune-mediated adverse reactions) and benefits (eg, rapid Hb improvemen

78 ship is important in controlling resistance, adverse reactions, and cost.

79 f alert clinicians in reporting of suspected adverse reactions, and the importance of internationally

80 ents who had ischemic events, who had severe adverse reactions, and who required life support were si

81 inii pneumonia (PCP) prophylactic agent, but adverse reactions are common among human immunodeficienc

82 mune reactivity, and fading of expression if adverse reactions are encountered.

83 More than half of all serious adverse reactions are identified 7 or more years after a

84 orted as well as veterinarian-diagnosed food adverse reactions are on the increase.

85 associated anaphylaxis and serious cutaneous adverse reactions are rare compared with C difficile inf

86 Serious adverse reactions are uncommon.

87 Our aim was to establish what types of adverse reactions are under-reported to the CSM by famil

88 ter studied, while they circumvented certain adverse reactions associated with FcgammaR engagement.

89 A total of 152 adverse reactions associated with heparin were identifie

90 come measure was the frequency and nature of adverse reactions associated with the transfusion.

91 No serious adverse reactions associated with the use of convalescen

92 SMC was well tolerated with no serious adverse reactions attributable to SMC drugs.

93 red with vehicle, with no reports of serious adverse reactions attributable to the therapy.

94 xtremely well at classifying known causes of adverse reactions (AUC 0.92).

95 ivity in hepatocytes, but might induce fewer adverse reactions because its receptor is largely restri

96 This modification is considered an adverse reaction, because it induces alterations of prot

97 n who received a dose of basiliximab without adverse reaction before an anticipated renal transplant

98 was the primary end point, whereas rates of adverse reactions being a secondary outcome.

99 employed as a diffusion barrier, preventing adverse reactions between coflowing solutions.

100 % of the 18,165 doses were tolerated without adverse reactions beyond the oropharynx, with no severe

101 Contaminated heparin was associated with adverse reactions by activating the contact system.

102 In allogeneic transplantation, such adverse reactions can occur by an indirect pathway when

103 associated with a greatly increased risk for adverse reactions compared with other herbs, and its use

104 ncompatibilities, aiming at the reduction of adverse reactions, cost and hospitalization period, and

105 ship between the radiopharmaceutical and the adverse reaction could not be determined.

106 t Reporting System and meaningfully cover an Adverse Reaction Database provided by Health Canada.

107 Self-reported food allergy and adverse reaction details, including anaphylaxis, were id

108 The most common adverse reaction during consolidation chemotherapy was g

109 Not all subjects experienced some adverse reactions during inhalation of SK-1211, all of w

110 Patients were monitored for adverse reactions during the dosing sessions and subsequ

111 Data, including efficacy, adverse reactions, dwell time, and catheter type, were c

112 cross validation scheme in which 10% of drug-adverse reaction edges were systematically deleted per f

113 role of systemic innate immune activation in adverse reactions elicited by foods in FPIES.

114 from the European Study of Severe Cutaneous Adverse Reactions (EuroSCAR; 1997-2001), we were not abl

115 antiviral drug abacavir, which causes severe adverse reactions exclusively in patients expressing the

116 Any subjective/objective adverse reactions experienced by the patient were typica

117 This study demonstrated a lack of clinical adverse reactions following two separate applications of

118 he acceptance, correlates of protection, and adverse reactions following vaccination in both young an

119 oduces protective immunity but may result in adverse reactions for some vaccinees.

120 Rates of adverse reactions for this macrocyclic contrast agent ar

121 earning has the potential to predict unknown adverse reactions from current knowledge.

122 adherence and persistence and by recognizing adverse reactions from glaucoma medications and surgerie

123 necessary to minimize the systemic or local adverse reactions from the active or inactive ingredient

124 cted a higher likelihood of both benefit and adverse reactions from treatment (experimental and stand

125 It is assumed that xenobiotic-induced adverse reactions have a strong genetic basis, but many

126 al use, at recommended doses, is safe and no adverse reactions have been described.

127 Severe adverse reactions have been observed in individuals with

128 tion competent vectors with the potential of adverse reactions have made attenuation a priority for n

129 ials and mechanisms by which they may induce adverse reactions have not received sufficient attention

130 attenuate visceral pain, but concerns about adverse reactions have restricted their availability.

131 confer no therapeutic benefit or trigger an adverse reaction in others.

132 The relative risks for an adverse reaction in persons using ephedra compared with

133 for myo/pericarditis did not detect cardiac adverse reactions in 382 study participants.

134 on immediate-type food allergy vs other food adverse reactions in companion animals, and compare this

135 The risk of adverse reactions in egg-allergic individuals should the

136 correlates of protection in males and reduce adverse reactions in females in an effort to increase ac

137 ession of IFN-alpha receptors often leads to adverse reactions in many organs.

138 y contribute to the increased risk of statin-adverse reactions in patients with DM2.

139 e role of mast cells in treatment-associated adverse reactions in patients with onchocerciasis, chang

140 the first few minutes of injection overcomes adverse reactions in pigs using two independent approach

141 benefit and those most likely to experience adverse reactions in response to a drug, and tailoring t

142 riences that was suggestive of low levels of adverse reactions in terms of family support and communi

143 ed with OSCS was epidemiologically linked to adverse reactions in this nationwide outbreak.

144 cause potentially significant (albeit rare) adverse reactions, including agranulocytosis and hepatot

145 446 mg], P < .001), but treatment-associated adverse reactions, including hyperglycemia and hypertens

146 letely clear or with minimum residual signs, adverse reactions, including pigmentary disturbance and

147 ministration of EMP-123 resulted in frequent adverse reactions, including severe allergic reactions i

148 combined with the extremely low incidence of adverse reactions, indicates the quality of these vaccin

149 clinically significant drug interactions and adverse reactions, indicating the importance of a detail

150 Adverse reactions involving skeletal muscle are the most

151 ond favorably to treatment or experience and adverse reaction is an essential step toward development

152 However, under-reporting of adverse reactions is frequent.

153 ne mechanism of ALP-induced severe cutaneous adverse reactions is poorly understood, and the T cell-r

154 m no therapeutic benefit to life-threatening adverse reactions, is influenced by variation in genes t

155 There were no differences in adverse reactions leading to discontinuation of LTBI tre

156 sit compliance, transaminase elevations, and adverse reactions leading to discontinuation of LTBI tre

157 One patient in each group had a serious adverse reaction; minor adverse reactions were more freq

158 Half experienced adverse reactions, mostly mild.

159 Serious adverse reactions necessitating hospitalisation occurred

160 Adverse reactions occurred in 6 patients (86%) and inclu

161 al neuropathy (CIPN) is a severe and painful adverse reaction of cancer treatment in patients that is

162 The adverse reaction of pericardial effusion has been added

163 Ten children in the intervention group had adverse reactions of a minor nature.

164 There were no side effects or adverse reactions of rhRLX given as an intravenous infus

165 here were 204 reports of radiopharmaceutical adverse reactions, of which 13 were considered invalid,

166 No suspected unexpected serious adverse reactions or severe adverse events related to va

167 whether peramivir affected outcome or caused adverse reactions other than rash.

168 For adverse reactions, our predictions were significantly en

169 ug demonstrated good integration and lack of adverse reaction over 28days.

170 y [WBC decrease (P = 0.04); gastrointestinal adverse reactions (P < 0.001)].

171 se escalation periods and has a high risk of adverse reactions, particularly in food allergy.

172 antigen (Ag) and carry a significant risk of adverse reactions, particularly in highly sensitized pat

173 HLA alleles associated with a range of these adverse reactions predominantly affecting the skin but a

174 symptoms; and the remaining five experienced adverse reactions preventing completion of dosing.

175 nd graft survival rates, renal function, and adverse reaction profiles for 12 months.

176 The observed adverse reaction rate to gadoteridol was lower than prev

177 hem, with high efficacy rate (98%) and a low adverse reaction rate when compared with oral administra

178 nd have been associated with relatively high adverse reaction rates.

179 Subjects with lower rates of adverse reactions, regardless of arm, experienced better

180 No participants had adverse reactions related to self-harm, suicidality, or

181 Despite the widespread usage of FCs, adverse reactions related to their consumption, includin

182 There were no serious adverse reactions reported.

183 tridium difficile infection, or drug-related adverse reactions requiring discontinuation.

184 he risk of lawsuits owing to possible severe adverse reactions--risks that are not counterbalanced by

185 (SJS) is a life-threatening severe cutaneous adverse reaction (SCAR), mainly caused by drugs.

186 iotics are a major cause of severe cutaneous adverse reactions (SCARs).

187 Boxed Warning, Warnings and Precautions, and Adverse Reactions sections of the labels of 870 drugs.

188 y increases the risk for coagulation-related adverse reactions, such as a bleeding or prothrombotic e

189 erienced significantly fewer and less severe adverse reactions than OIT-only-treated mice (P<.01) dur

190 All active dosages resulted in more adverse reactions than placebo, which were mainly mild a

191 induces extravascular hemolysis, an expected adverse reaction that is consistent with the presumed me

192 One unexpected, possibly related, serious adverse reaction that occurred 7 days after a 640 mug in

193 Next, a subset of adverse reactions that could be reliably detected in ano

194 n began a nationwide investigation of severe adverse reactions that were first detected in a single h

195 tial to improve patient safety by predicting adverse reactions that were not observed during randomis

196 esence of pollinosis (P = 0.004), history of adverse reaction to Bet v 1-associated food allergens (P

197 uilding on previous EAACI position papers on adverse reaction to foods and three recent systematic re

198 o fevers induced by viral infection or as an adverse reaction to live-virus vaccines such as measles,

199 epatic ischemia/reperfusion (I/R) is a major adverse reaction to liver transplantation, hemorrhagic s

200 tients' self-reported clinical history of an adverse reaction to penicillin and the clinicians' own m

201 a prior history of HBV infection nor a prior adverse reaction to the vaccine itself), 70 (22.5%; 95%

202 lerated the PET/MRI examination well, and no adverse reactions to (18)F-FTC-146 were reported.

203 ressing an enzyme previously associated with adverse reactions to a variety of pharmacologic agents (

204 arents (7.4%) and the reported prevalence of adverse reactions to additives (0.01-0.23%), which is hi

205 For the remaining patients, adverse reactions to bexarotene were generally mild to m

206 One of the major adverse reactions to chronic treatment with glucocortico

207 Adverse reactions to clopidogrel are not uncommon, and a

208 herapies remains important for patients with adverse reactions to conventional therapy, with defects

209 nt mechanism may be the predominant cause of adverse reactions to diclofenac.

210 Unknown adverse reactions to drugs available on the market prese

211 Adverse reactions to drugs increasingly are reported as

212 Adverse reactions to drugs may precipitate their removal

213 rlying disease susceptibility, efficacy, and adverse reactions to drugs remains a difficult problem.

214 ystematic studies, such as those identifying adverse reactions to drugs, are hindered because herbal

215 This risk was defined as the ratio of adverse reactions to ephedra versus other products, divi

216 Thirty-four patients with a history of adverse reactions to food, GI tract symptoms, and birch

217 35% of the population modify their diet for adverse reactions to food.

218 international workgroup convened through the Adverse Reactions to Foods Committee of the American Aca

219 tify the mechanism of antigen specificity of adverse reactions to foods in FPIES.

220 In addition, there appears to be no major adverse reactions to full-mouth root planing with or wit

221 The etiology of long-lasting adverse reactions to gel fillers used in cosmetic surger

222 0 of 11 subjects with PKU, and there were no adverse reactions to GMP.

223 containing ephedra accounted for 64% of all adverse reactions to herbs in the United States, yet the

224 p higher antibody responses, experience more adverse reactions to influenza vaccines, and show greate

225 Two participants had serious adverse reactions to intramuscular medroxyprogesterone a

226 Adverse reactions to intravenous administration of a non

227 None had adverse reactions to IVIg.

228 Adverse reactions to medications account for a substanti

229 articles from the taper junction can lead to Adverse Reactions to Metal Debris (ARMD) similar to thos

230 No clinical adverse reactions to multiple applications of EMD were n

231 Adverse reactions to oral azoles, drug interactions, and

232 Adverse reactions to peanut were reported in 1.5%, skin

233 (n = 1604), data were collected on reported adverse reactions to peanut, peanut sensitization (serum

234 specimens originating from 59 patients with adverse reactions to polyacrylamide gel, and 54 biopsies

235 include neurodegeneration, high cancer risk, adverse reactions to radiation and chemotherapy, pulmona

236 The prevalence of adverse reactions to radiopharmaceuticals reported in th

237 We assessed all reports of adverse reactions to radiopharmaceuticals that were subm

238 ITPA variants have only been associated with adverse reactions to specific drugs.

239 d not associated with an increase in serious adverse reactions to the drug.

240 no cases of osteonecrosis of the jaw and no adverse reactions to the injection of denosumab.

241 Adverse reactions to the OSCS-contaminated heparin were

242 ation, detailed contemporary descriptions of adverse reactions to the vaccine are needed to adequatel

243 The mice showed no adverse reactions to the vaccine, and they were protecte

244 n associated with reduced efficacy of and/or adverse reactions to therapeutics modified with or conta

245 ugs (NSAIDs) constitute only a subset of all adverse reactions to these drugs, but due to their sever

246 perience treatment-resistant inflammation or adverse reactions to these treatments, and there are cur

247 , approaches to mitigate the risk of serious adverse reactions to this new class of agent have emerge

248 e recorded adverse events, including serious adverse reactions to trial interventions.

249 ll serious adverse events, including serious adverse reactions to trial treatments.

250 len allergies are frequently associated with adverse reactions to various fruits, nuts, or vegetables

251 groups and there were no unexpected serious adverse reactions to xenon during hospital stay.

252 Many patients report adverse reactions to, and may not tolerate, statin thera

253 Adverse reactions typically occur within the first 90 da

254 Patients referred for immediate food adverse reactions underwent a consistent and standardize

255 The most common serious adverse reaction was infection occurring in five infants

256 No adverse reaction was observed.

257 One suspected unexpected serious adverse reaction was reported in the MAP group: bone mar

258 The frequency of adverse reactions was similar in both groups, suggesting

259 The adverse reactions we noted were transient anxiety during

260 Adverse reactions were assessed, and hemagglutination in

261 ata regarding VST production, infusions, and adverse reactions were compared.

262 Adverse reactions were consistent with the previously re

263 The percentages of successful sedations and adverse reactions were evaluated on the basis of data co

264 Nonhematologic adverse reactions were frequent but generally mild or mo

265 Adverse reactions were generally mild but more common wi

266 No adverse reactions were identified in addition to those s

267 Severe adverse reactions were limited to reversible panniculiti

268 Adverse reactions were markedly reduced during OIT escal

269 lly respond to the desensitization protocol, adverse reactions were minor and responded to treatment

270 The most common non-serious adverse reactions were moderate dehydration in one, mild

271 Adverse reactions were monitored.

272 Serious adverse reactions were more common in the continuous-iso

273 group had a serious adverse reaction; minor adverse reactions were more frequently reported in the d

274 Significant adverse reactions were not detected.

275 No severe adverse reactions were noted.

276 olled 102 patients by 7 July 2015; no severe adverse reactions were noted.

277 Fewer adverse reactions were observed in this study of non-nai

278 No adverse reactions were observed related to d-(18)F-FMT.

279 No adverse reactions were observed when three subcutaneous

280 No adverse reactions were observed.

281 No adverse reactions were observed.

282 No significant adverse reactions were observed.

283 No serious adverse reactions were observed.

284 No adverse reactions were produced by administration of lys

285 Abacavir adverse reactions were recently shown to be driven by dr

286 No serious adverse reactions were recorded and other safety measure

287 No adverse reactions were recorded during the tests.

288 Serious adverse reactions were recorded in two (1%) of 159 parti

289 All adverse reactions were recorded.

290 Adverse reactions were recorded.

291 No suspected unexpected serious adverse reactions were reported.

292 t with the underlying disease; no unexpected adverse reactions were reported.

293 No adverse reactions were seen in the adult or in 3 of the

294 Vaccination was safe and well tolerated; adverse reactions were transient and predominantly mild.

295 alliation of bone pain, and a low profile of adverse reactions (which are mild and manageable).

296 ght the role of those cytokines in mediating adverse reactions, which is of particular importance for

297 f factors might influence the association of adverse reactions with anti-IgA antibodies, including th

298 mal necrolysis (SJS/TEN) are rare but severe adverse reactions with high mortality.

299 of CT reduced, but did not eliminate, these adverse reactions without compromising adjuvancy.

300 deaths in the United States and hundreds of adverse reactions worldwide, revealing the vulnerability